Drug intelligence / Profile preview

fluvoxamine + methylphenidate

Development stage: Preclinical
Lead developer: Abbott
Modality: Small Molecules
Administration: Oral

Overview

This combination involves fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) primarily used for treating obsessive-compulsive disorder (OCD), and methylphenidate, a central nervous system stimulant used to treat attention deficit hyperactivity disorder (ADHD). The combination has been studied for its potential in treating treatment-refractory OCD and ADHD with comorbid depression. Methylphenidate may increase fluvoxamine levels, potentially enhancing its effects but also increasing the risk of side effects[1][2].

Targets

SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on fluvoxamine + methylphenidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluvoxamine + methylphenidate.

Explore the full profile